Lactobacillus GG in inducing and maintaining remission of Crohnss disease

DOI: 10.1186/1471-230x-4-5
BMC Gastroenterology, 2004, 4, 5.

#	Paper	IF	Citations
248	Commensal bacteria in the gut: learning who our friends are. **2004**, 20, 565-71		77
247	Place of probiotics. **2005**, 11, 318-25		16
246	Probiotics: facts and myths. **2005**, 11, 958-66		175
245	A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. **2005**, 11, 833-9		250
244	Probiotics: not just for treatment anymore. **2005**, 115, 174-7		17
243	Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics. **2005**, 34, 413-36, viii		53
242	The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. **2005**, 34, 465-82, ix		38
241	Probiotics as a treatment strategy for gastrointestinal diseases?. **2005**, 72, 57-68		63
240	Probiotics and prebiotics in chronic inflammatory bowel diseases. *World Journal of Gastroenterology*, **2006**, 12, 5941-50	5.6	113
239	Modifying the Human Intestinal Microbiota with Prebiotics. **2006**, 285-314		5
238	Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. **2006**, 42, 454-75		106
237	Probiotics and bowel inflammation. **2006**, 247, 1-4		
236	Probiotics in the treatment of inflammatory bowel disease. **2006**, 40, 260-3		67
235	Probiotics and their potential health claims. **2006**, 64, 265-74		133
234	Evolving knowledge and therapy of inflammatory bowel disease. **2006**, 5, 197-209		141
233	Nutrition orale et entérale thérapeutique dans la maladie de Crohn de l'adulte : études et stratégies récentes. **2006**, 20, 17-25		1
232	Probiotics: do they help to control intestinal inflammation?. **2006**, 1072, 339-50		21

231	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. **2006**, 8, 486-98		37
230	Probiotics for maintenance of remission in Crohn's disease. **2006**, CD004826		95
229	Medical management of Crohn's disease: current therapy and recent advances. **2006**, 2, 109-20		1
228	Digestive Physiology and the Role of Microorganisms. **2006**, 15, 136-144		55
227	Probiotics in the Management of Inflammatory Bowel Diseases?. *American Journal of Gastroenterology*, **2007**, 102, S22-S28	0.7	3
226	Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. **2007**, 2, 401-29		34
225	Probiotics, prebiotics, and inflammatory bowel disease. **2007**, 90-116		1
224	Probiotic agents in the treatment of irritable bowel syndrome. **2007**, 35, 583-9		13
223	Probiotics and prebiotics: effects on diarrhea. **2007**, 137, 803S-11S		184
222	[Probiotics and prebiotics in inflammatory bowel disease]. **2007**, 30, 419-25		1
221	Probiotics for preventing relapse or recurrence in Crohn's disease involving the ileum: Are there reasons for failure?. **2007**, 1, 47-52		9
220	Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. **2007**, 66, 307-15		141
219	High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. **2007** , 22, 1199-204		109
218	Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. **2007**, 132, 562-75		567
217	Prebiotic and synbiotic fructooligosaccharide administration fails to reduce the severity of experimental colitis in rats. **2007**, 50, 1061-9		31
216	A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. **2008**, 53, 2524-31		143
215	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. **2008**, 52, 906-12		27
214	Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun. **2008**, 14, 1068-83		168

213	Role of probiotic therapy in IBD. **2008**, 14, 1597-605		70
212	Probiotics, prebiotics, and synbiotics. **2008**, 111, 1-66		395
211	Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. **2008**, 151, 528-35		257
210	Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. **2008**, 65, 453-67		100
209	Role of Probiotics in Health and Diseases. **2008**, 257-375		2
208	Prebiotics. **2008**, 533-581		6
207	Impact of lactic acid bacteria on oxidative DNA damage in human derived colon cells. **2008**, 46, 1221-9		50
206	Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. **2008**, 14, 1585-96		224
205	Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. **2008**, 60, 757-67		63
204	Probiotics in clinical practice: an overview. **2008**, 36 Suppl 1, 1A-53A		49
203	Rationale for probiotic treatment strategies in inflammatory bowel disease. **2008**, 2, 337-55		15
202	Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. **2008**, 12, 301-12		16
201	Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis. **2008**, 21, 401-7		5
200	Probiotics for induction of remission in Crohn's disease. **2008**, CD006634		53
199	Pathophysiology of Inflammatory Bowel Diseases. **2008**, 341-373		0
198	Role of the intestinal barrier in inflammatory bowel disease. *World Journal of Gastroenterology*, **2008**, 14, 401-7	5.6	199
197	The evidence to support health claims for probiotics. **2008**, 138, 1250S-4S		83
196	Microecology, obesity, and probiotics. **2008**, 15, 422-7		46

195	Probiotics and Prebiotics as Functional Ingredients in Inflammatory Bowel Disease. **2008**, 43, 235-242	2
194	Probiotics in the treatment of human inflammatory bowel diseases: update 2008. **2008**, 42 Suppl 2, S97-103	25
193	Inflammatory disease processes and interactions with nutrition. **2009**, 101 Suppl 1, S1-45	247
192	A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora. **2009**, 58, 1104-12	35
191	Probiotics in pediatric inflammatory bowel diseases. **2009**, 11, 238-47	2
190	Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. **2009**, 39, 103-9	44
189	Effect of probiotics on intestinal barrier function. **2009**, 1165, 183-9	91
188	Galacto-oligosaccharides and Other Products Derived from Lactose. **2009**, 121-201	37
187	Intestinal bacteria and inflammatory bowel disease. **2009**, 46, 25-54	67
186	Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions. **2010**, 3, 117-27	6
185	Genetic polymorphisms of CYP2D6 oxidation in patients with inflammatory bowel disease. **2010**, 55, 1037-43	5
184	Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. **2010**, 162, 306-14	74
183	What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease?. **2010**, 19, 904-16	14
182	Probiotic Treatment of Colitis in Animal Models and People. **2010**, 571-587	
181	Use of probiotics in gastrointestinal disorders: what to recommend?. **2010**, 3, 307-19	146
180	Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. **2010**, 140, 690S-7S	72
179	How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation. **2010**, 2010, 574568	21
178	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. **2010**, 4, 28-62	1071

177	Recent developments and perspectives in the investigation of probiotic effects. **2010**, 300, 3-10	70
176	[Microbiota and probiotics: effects on human health]. **2010**, 56, 611-50	10
175	Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease. **2010**, 6, 47-54	28
174	Probiotics and Prebiotics. **2010**, 205-227	9
173	Probiotics and prebiotics in pediatrics. **2010**, 126, 1217-31	289
172	Gut microbiota and inflammation. **2011**, 3, 637-82	264
171	Challenges of Beneficial Health Claims. **2011**, 243-268	
170	Probiotics in inflammatory bowel diseases and associated conditions. **2011**, 3, 245-64	51
169	Do probiotic preparations for humans really have efficacy?. **2011**, 22, 10128	15
168	Probiotics in the treatment of human inflammatory bowel diseases: update 2011. **2011**, 45 Suppl, S139-44	64
167	Encapsulation of probiotic living cells: From laboratory scale to industrial applications. **2011**, 104, 467-483	528
166	Review on efficacy and health services research studies of complementary and alternative medicine in inflammatory bowel disease. **2011**, 17, 403-9	17
165	Aberrant response to commensal Bacteroides thetaiotaomicron in Crohn's disease: an ex vivo human organ culture study. **2011**, 17, 1201-8	18
164	Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. **2011**, 2011, 971938	44
163	The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential. **2011**, 19, 155-173	3
162	Probiotics in luminal gastroenterology: the current state of play. **2012**, 42, 1287-91	17
161	A gastroenterologist's guide to probiotics. **2012**, 10, 960-8	95
160	Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. **2012**, 41, 821-42	20

159	Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract. **2012**, 57, 175-82		8
158	Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. **2012**, 11, 161		59
157	Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. **2012**, 72, 803-23		156
156	[Not Available]. **2012**, 41, 123-33		1
155	Probiotics for the treatment of inflammatory bowel disease. **2012**, 14, 324-33		80
154	Any role for probiotics in the therapy or prevention of autoimmune diseases? Up-to-date review. **2013**, 10,		9
153	Intestinal Microflora and Diet in Health. **2013**, 719-738		3
152	An overview of the last advances in probiotic and prebiotic field. **2013**, 50, 1-16		279
151	Might patients with immune-related diseases benefit from probiotics?. **2013**, 29, 583-6		29
150	Probiotics and clinical effects: is the number what counts?. **2013**, 25, 193-212		41
149	RETRACTED: Preventative and Therapeutic Role of Probiotics in Various Allergic and Autoimmune Disorders: An Up-to-Date Literature Review of Essential Experimental and Clinical Data. **2013**, 18, 121-151		2
148	Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. **2013**, 2013, 435268		116
147	Probiotics. **2013**, 31, 385-7		5
146	Actual concept of "probiotics": is it more functional to science or business?. *World Journal of Gastroenterology*, **2013**, 19, 1527-40	5.6	38
145	Are probiotics or prebiotics useful in pediatric irritable bowel syndrome or inflammatory bowel disease?. *Frontiers in Medicine*, **2014**, 1, 23	4.9	28
144	Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. *World Journal of Gastroenterology*, **2014**, 20, 11505-24	5.6	123
143	Non-pulmonary allergic diseases and inflammatory bowel disease: a qualitative review. *World Journal of Gastroenterology*, **2014**, 20, 11023-32	5.6	16
142	Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?. **2014**, 73, 490-7		30

141	Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. **2014**, 20, 21-35	260
140	Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. **2014**, 7, 473-87	192
139	Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. **2014**, 126, 7-19	192
138	Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's?. **2014**, 28, 399-409	10
137	Probiotics, prebiotics and the gastrointestinal tract in health and disease. **2014**, 22, 135-54	37
136	Probiotic actions on diseases: implications for therapeutic treatments. **2014**, 5, 625-34	14
135	The Potential for use of Probiotics in Pediatric Irritable Bowel Syndrome and Inflammatory Bowel Disease. **2014**, 2, 235-240	1
134	Inflammatory Bowel Disease. **2015**, 347-374	
133	Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. **2015**, 6, 209-17	23
132	Role of Probiotics in Crohn's Disease and in Pouchitis. **2015**, 49 Suppl 1, S46-9	26
131	Lactobacillus rhamnosus GG supernatant upregulates serotonin transporter expression in intestinal epithelial cells and mice intestinal tissues. **2015**, 27, 1239-48	20
130	Geriatric Respondents and Non-Respondents to Probiotic Intervention Can be Differentiated by Inherent Gut Microbiome Composition. **2015**, 6, 944	15
129	Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases. **2015**, 16, 20841-58	66
128	The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. **2015**, 2015, 505878	185
127	Post-operative recurrence in Crohn's disease. Critical analysis of potential risk factors. An update. **2015**, 13, 330-47	24
126	Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. **2015**, 30, 747-59	21
125	Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease. **2015**, 21, 1674-82	102
124	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. **2015**, 149, 191-212	110

123	The gut microbiota and inflammatory bowel disease. **2015**, 37, 47-55		392
122	Nutraceutical Supplements for Inflammatory Bowel Disease. **2015**, 30, 551-8		8
121	New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. **2015**, 60 Suppl 2, S108-21		151
120	Probiotics prevent Hirschsprung's disease-associated enterocolitis: a prospective multicenter randomized controlled trial. **2015**, 30, 105-10		39
119	Evaluation of biochemical and molecular methods for Lactobacillus reuteri strains differentiation. **2015**, 60, 137-41		2
118	Diet therapy for inflammatory bowel diseases: The established and the new. *World Journal of Gastroenterology*, **2016**, 22, 2179-94	5.6	88
117	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. **2016**, 17,		43
116	Microbiota at the crossroads of autoimmunity. **2016**, 15, 859-69		82
115	The role of dietary supplements in inflammatory bowel disease: a systematic review. **2016**, 28, 1357-1364		32
114	Therapeutic modulation of gut microbiota in inflammatory bowel disease: More questions to be answered. **2016**, 17, 800-810		26
113	Clinical Uses of Probiotics. **2016**, 95, e2658		104
112	Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India. **2016**, 51, 660-71		28
111	Probiotics and prebiotics in Crohn's disease therapies. **2016**, 30, 81-8		34
110	Prebiotics and Probiotics in Inflammatory Bowel Disease (IBD). **2016**, 131-147		2
109	Review of the role of probiotics in gastrointestinal diseases in adults. **2017**, 40, 417-429		23
108	Review of the role of probiotics in gastrointestinal diseases in adults. **2017**, 40, 417-429		14
107	Dietary and enteral interventions for Crohn's disease. **2017**, 44, 69-73		24
106	Probiotics in Inflammatory Bowel Disease. **2017**, 46, 769-782		95

105	Intestinal microbiome in scleroderma: recent progress. **2017**, 29, 553-560	26
104	An Overview of Probiotic Research. **2017**, 293-357	1
103	Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. **2017**, 46, 389-400	206
102	The Different Drummer: Non-traditional Therapeutic Approaches. **2017**, 205-216	
101	Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases. **2017**, 152, 415-429.e15	79
100	Probiotics for cure of Helicobacter pylori infection: A review. **2017**, 20, 2215-2222	5
99	Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. **2017**, 174, 1426-1449	82
98	The autoimmunity-oral microbiome connection. **2017**, 23, 828-839	84
97	Intestinal Microbiota and Diet in Health. **2017**, 811-834	1
96	Clinical Evidence for the Microbiome in Inflammatory Diseases. **2017**, 8, 400	33
95	Probiotic Treatment in Crohn Disease. **2017**, 331-341	1
94	The role of the gut microbiome in systemic inflammatory disease. **2018**, 360, j5145	202
93	Consensus and contentious statements on the use of probiotics in clinical practice: A south east Asian gastro-neuro motility association working team report. **2018**, 33, 1707-1716	13
92	Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review. **2018**, 233, 2091-2103	168
91	The role of the intestinal microbiota in the pathogenesis and treatment of inflammatory bowel diseases. **2018**, 29, 21-27	
90	Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. **2018**, 47, 26-42	107
89	The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. **2018**, 97, e13792	33
88	Use of Probiotics to Prevent Celiac Disease and IBD in Pediatrics. **2019**, 1125, 69-81	4

87	Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis. *Frontiers in Medicine*, **2018**, 5, 124	4.9	179
86	Effectiveness of Multistrain Versus Single-strain Probiotics: Current Status and Recommendations for the Future. **2018**, 52 Suppl 1, Proceedings from t, S35-S40		43
85	Opportunistic Food-Borne Pathogens. **2018**, 269-306		4
84	Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?. *American Journal of Gastroenterology*, **2018**, 113, 1125-1136	0.7	27
83	Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. **2019**, 70, 20-29		40
82	Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. **2019**, 19, 1343-1355		3
81	Microbiota, Prebiotics, Antibiotics and Fecal Microbiota Transfer. **2019**, 113-124		2
80	First and second generation probiotic therapeutics for Inflammatory Bowel Disease. **2019**, 9, 100159		11
79	An introduction of the role of probiotics in human infections and autoimmune diseases. **2019**, 45, 413-432		26
78	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. **2019**, 49, 978-996		8
77	European Crohn's and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. **2019**, 13, 673-685e		38
76	Novel Approaches for Pouchitis and Colitis With or Without Diversion. **2019**, 529-535		1
75	Therapy for Crohn's Disease. **2019**, 150-172		
74	Use of Probiotics in Inflammatory Bowel Disease. **2019**, 149-154		
73	Thirty Years of Lactobacillus rhamnosus GG: A Review. **2019**, 53 Suppl 1, S1-S41		90
72	The Microbiome in Patients With Inflammatory Diseases. **2019**, 17, 243-255		24
71	Effect of Probiotic Use on Adverse Events in Adult Patients with Inflammatory Bowel Disease: a Retrospective Cohort Study. **2020**, 12, 152-159		16
70	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. **2020**, 11, 62-69		16

69	Beneficial effects of ginger on prevention of obesity through modulation of gut microbiota in mice. **2020**, 59, 699-718	54
68	The microbiome and inflammatory bowel disease. **2020**, 145, 16-27	155
67	Efficacy of Dietary Supplements in Inflammatory Bowel Disease and Related Autoimmune Diseases. **2020**, 12,	14
66	Probiotics for induction of remission in Crohn's disease. **2020**, 7, CD006634	13
65	Anti-Inflammatory and Gut Microbiota Modulatory Effect of Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model. **2020**, 8,	8
64	AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders. **2020**, 159, 708-738.e4	35
63	Study of the alleviation effects of a combination of Lactobacillus rhamnosus and inulin on mice with colitis. **2020**, 11, 3823-3837	33
62	Gut Microbiome and Gastrointestinal Disorders. **2021**, 41-91	
61	Gut Microbiota Dysbiosis and Chronic Intestinal Inflammation. **2021**, 423-423	
60	Phenyl lactic acid alleviates Typhimurium-induced colitis regulating microbiota composition, SCFA production and inflammatory responses. **2021**, 12, 5591-5606	3
59	Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis. **2021**, 60, 2855-2875	26
58	Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. **2021**, 10,	17
57	Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. **2021**, 11,	16
56	Gut mucosal and adipose tissues as health targets of the immunomodulatory mechanisms of probiotics. **2021**, 112, 764-779	1
55	Temporal dynamics of probiotic Lacticaseibacillus casei and rhamnosus abundance in a fermented dairy product evaluated using a combination of cultivation-dependent and -independent methods. **2021**, 148, 111750	3
54	Complementary and Alternative Medicine in Gastroenterology. 2521-2532	1
53	Probiotics and Chronic Gastrointestinal Disease. **2009**, 949-975	1
52	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. **2011**, 123-150	2

51	The Protective Role of Probiotics in Disturbed Enteric Microbiota. **2011**, 221-261		2
50	Lactic Acid Bacteria in Health and Disease. **2014**, 303-374		6
49	Probiotics and fecal microbiota transplantation in surgical disorders. **2018**, 29, 37-43		2
48	Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. *Journal of Clinical Investigation*, **2011**, 121, 2242-53	15.9	231
47	Intestinal Microbiome, Small Intestinal Bacterial Overgrowth and Inflammatory Bowel Diseases - What are the Connections?. *Current Health Sciences Journal*, **2015**, 41, 197-203	0.3	1
46	Nutritional Support and Probiotics as a Potential Treatment of IBD. *Current Drug Targets*, **2020**, 21, 1417-1427	3	2
45	Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?. *Current Clinical Pharmacology*, **2020**, 15, 216-233	2.5	13
44	Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. *World Journal of Gastroenterology*, **2005**, 11, 5185-92	5.6	89
43	Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. *World Journal of Gastroenterology*, **2006**, 12, 5978-86	5.6	88
42	Probiotics in inflammatory bowel disease: Pathophysiological background and clinical applications. *World Journal of Immunology*, **2013**, 3, 31	0.5	7
41	The Mechanisms of Immune System Regulation by Probiotics in Immune-Related Diseases. *Journal of Pharmacy and Nutrition Sciences (discontinued)*, **2016**, 6, 105-111	0.3	2
40	Inflammatory Bowel Disease. **2007**, 541-554		
39	Probiotics in the Management of Inflammatory Bowel Diseases?. *American Journal of Gastroenterology*, **2007**, 102, 22-28	0.7	
38	Probiotics in Crohn's Disease. **2009**, 165-179		
37	Inflammatory Bowel Disease. **2009**,		
36	Application of Functional Dairy Products from IBS to IBD. **2009**, 375-393		
35	Probiotics and Inflammatory Immune Responses. **2010**, 591-610		
34	Crohn's Disease. **2010**, 211-231		

33	Inflammatory Bowel Disease. **2012**, 464-474.e5		
32	Probiotic Therapy. **2013**, 313-323		
31	Probiotics and Prebiotics in Crohn's Disease. **2013**, 410-429		
30	Probiotics in Gastrointestinal Diseases. 255-269		
29	The application of probiotics for the treatment of inflammatory bowel diseases, hepatopathy, and infectious diseases. *Russian Journal of Evidence-Based Gastroenterology*, **2017**, 6, 35	0.3	
28	Probiotic Therapy. **2017**, 357-367		
27	15 Inflammatory Bowel Disease. **2017**, 347-374		
26	An Overview of the Therapeutic Aspect of Living Drugs Probiotics. *Health Information Systems and the Advancement of Medical Practice in Developing Countries*, **2019**, 1-34	0.2	
25	Probiotics for inflammatory bowel disease. 250-259		
24	Biological Approach in the Treatment of Crohn's Disease. **2006**, 157-170		
23	Probiotic Therapy. **2008**, 351-361		
22	Probiotics in the management of inflammatory bowel disease. *MedGenMed: Medscape General Medicine*, **2005**, 7, 19		2
21	The emerging therapeutic role of probiotics in inflammatory bowel disease. *Gastroenterology and Hepatology*, **2008**, 4, 634-40	0.7	3
20	PROBIOTIC APPROACHES FOR TARGETING INFLAMMATORY BOWEL DISEASE: AN UPDATE ON ADVANCES AND OPPORTUNITIES IN MANAGING THE DISEASE. *International Journal of Probiotics and Prebiotics*, **2016**, 11, 99-116	0.4	3
19	Probiotics: current regulatory aspects of probiotics for use in different disease conditions. **2022**, 465-499		
18	Aktualisierte S3-Leitlinie Diagnostik und Therapie des Morbus Crohn der Deutschen Gesellschaft f Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) August 2021 AWMF-Registernummer: 021-004. *Zeitschrift Fur Gastroenterologie*, **2022**, 60, 332-418	1.6	5
17	Nutraceuticals and Diet Supplements in Crohn's Disease: A General Overview of the Most Promising Approaches in the Clinic.. *Foods*, **2022**, 11,	4.9	1
16	Probiotics in Crohn's disease remission: a systematic review. *Archivos Latinoamericanos De Nutricion* , **2022**, 72, 50-59	0.1	0

15	Relationship between gut microbiota and colorectal cancer: Probiotics as a potential strategy for prevention. *Food Research International*, **2022**, 156, 111327	7	3
14	Probiotics for gastrointestinal health and disease treatment. **2022**, 431-448		
13	Manipulation of Gut Microbiota as a Key Target for Crohn's Disease. *Frontiers in Medicine*, 9,	4.9	0
12	Title: Consensus Guidelines on the Nutritional Assessment and Dietary Management of Patients with Inflammatory Bowel Disease (IBD). *Journal of Human Nutrition and Dietetics*,	3.1	2
11	Mechanisms and applications of probiotics in healthcare industry. **2022**, 225-257		2
10	Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. **2022**, 15, e249020		0
9	The emerging microbiome based approaches to IBD therapy: From SCFAs to urolithin A.		0
8	Inflammatory bowel disease therapeutic strategies through the modulation of the microbiota: how and when to introduce pre-, pro-, syn- or postbiotics?.		1
7	Microbial-Derived Tryptophan Catabolites, Kidney Disease and Gut Inflammation. **2022**, 14, 645		0
6	Inflammatory bowel disease - A peek into the bacterial community shift and algae-based □biotic□ approach to combat the disease. **2022**, 129, 210-220		1
5	The synbiotic mixture of Bacillus licheniformis and Saccharomyces cerevisiae extract aggravates dextran sulfate sodium induced colitis in rats. **2022**, 18,		0
4	ESPEN guideline on Clinical Nutrition in inflammatory bowel disease. **2023**,		3
3	Fermented foods, prebiotics, and probiotics. **2023**, 239-263		0
2	The Role of Probiotics in Inducing and Maintaining Remission in Crohn□ Disease and Ulcerative Colitis: A Systematic Review of the Literature. **2023**, 11, 494		0
1	The Potential Therapeutic Role of Lactobacillaceae rhamnosus for Treatment of Inflammatory Bowel Disease. **2023**, 12, 692		0